Browse the full insider trade history of NEWLINK GENETICS CORP, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Market capitalisation: €196.6m. The latest transaction was reported on 4 February 2016 (Cession). Among the most active insiders: Link Charles J. Jr.. All data is openly available.
18
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
13 ops.
Sell Volume
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 24,711 of 24,987 companies
7.4
score / 100
Value
6
Quality
9
FCF yld-23%
Earn yld-96%
EV/EBITDA·
ROE-29%
Gross mgn14%
Net mgn-61%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
NEWLINK GENETICS CORP is a biopharmaceutical company focused on developing immunotherapy treatments for cancer and other diseases. It is listed on NASDAQ under the ticker NLNK.